StratDeck

Two stocks in Healthcare

Synektik Spółka Akcyjna vs UCB: profit, growth, debt and price compared

Synektik Spółka Akcyjna is stronger on 4 of 7 figures: profit margin, sales growth, debt and dividend. UCB is stronger on 2: price for its expected profit and price trend.

Figures as of 20 November 2026Yahoo Finance
Explore Synektik Spółka Akcyjna's storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Synektik Spółka Akcyjna and UCB side by side
Synektik Spółka AkcyjnaSNT.WAUCBUCB.BR
Net marginStronger: 44.8%25.7%
Revenue growth, past yearStronger: +89.50%+22.50%
Debt to equityStronger: 19.4%30.8%
Forward P/E25.9×Stronger: 18.7×
Dividend yieldStronger: 3.40%0.51%
AnalystsBuy · 5Buy · 19
From its 200-day average−3.1%Stronger: +17.2%

Share price over the past year

  • Synektik Spółka Akcyjna+10.1%
  • UCB+17.6%

26 Nov 202520 Nov 2026

Synektik Spółka Akcyjna or UCB: which is stronger?

  • SNT.WA

    Which is more profitable?

    Synektik Spółka Akcyjna keeps more of each sale as profit: 44.8% against 25.7%.

  • SNT.WA

    Which is growing its sales faster?

    Synektik Spółka Akcyjna is growing its sales faster: +89.50% over the past year, against +22.50%.

  • SNT.WA

    Which has borrowed less?

    Synektik Spółka Akcyjna has borrowed less: its debt is 19.4% of what its shareholders own, against 30.8% for UCB.

  • UCB.BR

    Which costs less for the profit it is expected to make?

    UCB costs less for the profit it is expected to make: 18.7× its forward earnings, against 25.9×.

  • SNT.WA

    Which pays more in dividends?

    Synektik Spółka Akcyjna pays more back in dividends for what a share costs: 3.40% a year, against 0.51%.

  • Which do analysts rate higher?

    Analysts rate both the same: Buy.

  • UCB.BR

    Which is in the stronger price trend?

    UCB's price is in the stronger trend: 17.2% above its 200-day average, against 3.1% below.

What each company does

SNT.WASynektik Spółka Akcyjna

Synektik Spółka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland.

UCB.BRUCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.

Reports results on 25 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.